Topoisomerase II Inhibitors [Pharmacological Action]
Tree Number(s): D059005
MeSH Unique ID: D059005
- coumermycin (Supplementary Concept)
- flumequine (Supplementary Concept)
- valrubicin (Supplementary Concept)
- amifloxacin (Supplementary Concept)
- asulacrine (Supplementary Concept)
- 3'-deamino-3'-hydroxydoxorubicin (Supplementary Concept)
- merbarone (Supplementary Concept)
- lomefloxacin (Supplementary Concept)
- temafloxacin (Supplementary Concept)
- 5,11-dimethyl-5H-indolo(2,3-b)quinoline (Supplementary Concept)
- carbobenzoxycoumarin (Supplementary Concept)
- chlorobiocic acid (Supplementary Concept)
- 9'-fluoro-10'-(4-methyl-1-piperazinyl)-7'-oxospiro(cyclopropane-1,3'(2'H)-(7H)pyrido(1,2,3-de)(1,4)benzoxazine)-6'-carboxylic acid (Supplementary Concept)
- clinafloxacin (Supplementary Concept)
- sobuzoxane (Supplementary Concept)
- N-(2'-(dimethylamino)ethyl)acridine-4-carboxamide (Supplementary Concept)
- rufloxacin (Supplementary Concept)
- sparfloxacin (Supplementary Concept)
- nadifloxacin (Supplementary Concept)
- BE 10988 (Supplementary Concept)
- BE 13793C (Supplementary Concept)
- 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (Supplementary Concept)
- ulifloxacin (Supplementary Concept)
- prulifloxacin (Supplementary Concept)
- grepafloxacin (Supplementary Concept)
- azatoxin (Supplementary Concept)
- sitafloxacin (Supplementary Concept)
- balofloxacin (Supplementary Concept)
- pazufloxacin (Supplementary Concept)
- 2-(4-methoxyphenyl)-5-((4-methylpiperazin-1-yl)-3H-imidazo(4,5-b)pyridin-2-yl)-3H-imidazo(4,5-b)pyridine (Supplementary Concept)
- trovafloxacin (Supplementary Concept)
- bastadin 14 (Supplementary Concept)
- 5,8-bis(2-aminoethylamino)-1-azaanthracene-9,10-dione (Supplementary Concept)
- 1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarboxyic acid (Supplementary Concept)
- PD 138312 (Supplementary Concept)
- Ro 47-3359 (Supplementary Concept)
- cyclothialidine (Supplementary Concept)
- N-(2-(dimethylamino)ethyl)-2-(4-pyridyl)quinoline-8-carboxamide (Supplementary Concept)
- pixantrone (Supplementary Concept)
- BE 22179 (Supplementary Concept)
- GR 122222X (Supplementary Concept)
- bis(helenalinyl)glutarate (Supplementary Concept)
- bis(isoalantodiol-B)glutarate (Supplementary Concept)
- 8-desaminobatracylin (Supplementary Concept)
- 8-azabatracylin (Supplementary Concept)
- A 62176 (Supplementary Concept)
- A 85226 (Supplementary Concept)
- CJ 12371 (Supplementary Concept)
- CJ 12372 (Supplementary Concept)
- FD 501 (Supplementary Concept)
- makaluvamine N (Supplementary Concept)
- N-(2-(dimethylamino)ethyl)-5-methyl-4-acridinecarboxamide (Supplementary Concept)
- 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one (Supplementary Concept)
- alatrofloxacin (Supplementary Concept)
- PD 161148 (Supplementary Concept)
- PD 135042 (Supplementary Concept)
- PD 160793 (Supplementary Concept)
- CJ 12373 (Supplementary Concept)
- tridemethyl-N-(4'-nitrobenzoyl)deacetylthiocolchicine (Supplementary Concept)
- 1,2,3-O-acetyl-1,2,3-demethyl-N-(4'-nitrobenzoyl)deacetylthiocolchicine (Supplementary Concept)
- SR 107 (Supplementary Concept)
- SR 103 (Supplementary Concept)
- NSC 659687 (Supplementary Concept)
- Ruthenium Ben (Supplementary Concept)
- Ruthenium Sal (Supplementary Concept)
- makaluvamine I (Supplementary Concept)
- makaluvamine H (Supplementary Concept)
- 2,3-dihydroindolizino(7,6,5-kl)acridinium chloride (Supplementary Concept)
- matadine (Supplementary Concept)
- N,N-bis(3-(5-bromoacridine-4-carboxamido)propyl)methylamine (Supplementary Concept)
- N,N-bis(3-(5-methylacridine-4-carboxamido)propyl)methylamine (Supplementary Concept)
- 4'-O-demethyl-4-(4''-(benzimidazol-2''-yl)anilino)-4-desoxypodophyllotoxin (Supplementary Concept)
- GL 331 (Supplementary Concept)
- UCT 1072M1 (Supplementary Concept)
- UCT 1072M2 (Supplementary Concept)
- 7-(4-(4-tert-butylbenzyloxy)-1H-indazol-3-ylmethylsulfanyl)-4-methylcoumarin (Supplementary Concept)
- 4-demethoxy-3'-deamino-3'-hydroxydoxorubicin (Supplementary Concept)
- 4-demethoxy-3'-deamino-4'-deoxy-4'-aminodaunorubicin (Supplementary Concept)
- neocryptolepine (Supplementary Concept)
- alpha-lapachone (Supplementary Concept)
- eleutherin (Supplementary Concept)
- 9-bromophenazine-4-carboxamide (Supplementary Concept)
- garenoxacin (Supplementary Concept)
- 1-(3'-hydroxypropyl)-4,6,8-trimethylfuro(2,3-h)quinolin-2(1H)-one (Supplementary Concept)
- isoaurostatin (Supplementary Concept)
- 4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide (Supplementary Concept)
- ardisin (Supplementary Concept)
- 1,3,4,5,6,7,8,10-octahydro-14-hydroxy-12-methoxy-11-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-6-thioxo-9,2,5-benzoxanthiaazacyclododecine-10-one (Supplementary Concept)
- 1,3,4,5,6,7,8,9,10,12-decahydro-16-hydroxy-14-methoxy-13-methyl-4-(3-methyl-1,2,4-oxadiazol-5-yl)-6-thioxo-11,2,5-benzoxathiaazacyclotetradecine-12-one (Supplementary Concept)
- 4-methyl-7-(tetradecanoyl)-2H-1-benzopyran-2-one (Supplementary Concept)
- 5-(2-(5-chloroindol-3-yl)vinyl)pyrazole (Supplementary Concept)
- WCK 1734 (Supplementary Concept)
- leptosin F (Supplementary Concept)
- VRT 125853 (Supplementary Concept)
- methyl 3-(4-(bis(2-chloroethyl)amino)phenyl)-2-(2-(4-((N-isopropyl)amidino)phenyl)furan-5-carboxamido)propanoate (Supplementary Concept)
- 3-O-coumaroylbetulinic acid (Supplementary Concept)
- 2-(2'-(dimethylamino)ethyl)-1,2-dihydro-7-ethoxydibenz(de,h)isoquinoline-1,3-dione (Supplementary Concept)
- 3-amino-7-(3-(1-aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-1H-quinazoline-2,4-dione (Supplementary Concept)
- 7-(3-(1-aminoethyl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methyl-1H-quinazoline-2,4-dione (Supplementary Concept)
- besifloxacin (Supplementary Concept)
- antofloxacin (Supplementary Concept)
- 2-(2-dimethylamino)-6-thia-2-azabenzo(def)chrysene-1,3-dione (Supplementary Concept)
- WRC 213 (Supplementary Concept)
- PNU-286607 (Supplementary Concept)
- PF 03376056 (Supplementary Concept)
- novobiocin 401 (Supplementary Concept)
- 2-(3',4'-dihydroxyphenyl)-5,7-dihydroxy-3-(2'',6''-di-O-(3'''-(4-fluorophenylpropanoyl)))galactosyl-4H-chromen-4-one (Supplementary Concept)
- finafloxacin (Supplementary Concept)
- 4-benzoyl-1-(4-methyl-imidazol-5-yl)carbonylthiosemicarbazide (Supplementary Concept)
- kibdelomycin A (Supplementary Concept)
- etirinotecan pegol (Supplementary Concept)
- zoliflodacin (Supplementary Concept)
- Carubicin (MeSH Term)
- Cinoxacin (MeSH Term)
- Ciprofloxacin (MeSH Term)
- Daunorubicin (MeSH Term)
- Doxorubicin (MeSH Term)
- Etoposide (MeSH Term)
- Mitoxantrone (MeSH Term)
- Nalidixic Acid (MeSH Term)
- Norfloxacin (MeSH Term)
- Oxolinic Acid (MeSH Term)
- Teniposide (MeSH Term)
- Ofloxacin (MeSH Term)
- Aclarubicin (MeSH Term)
- Epirubicin (MeSH Term)
- Idarubicin (MeSH Term)
- Enoxacin (MeSH Term)
- Pefloxacin (MeSH Term)
- Fleroxacin (MeSH Term)
- Levofloxacin (MeSH Term)
- Dexrazoxane (MeSH Term)
- Moxifloxacin (MeSH Term)
- Gatifloxacin (MeSH Term)
- Gemifloxacin (MeSH Term)